Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Silence Therapeutics plc before investing.

In this article, we go over a few key elements for understanding Silence Therapeutics plc’s stock price such as:

• Silence Therapeutics plc’s current stock price and volume
• Why Silence Therapeutics plc’s stock price changed recently
• Upgrades and downgrades for SLN from analysts
• SLN’s stock price momentum as measured by its relative strength

About Silence Therapeutics plc (SLN)

Before we jump into Silence Therapeutics plc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

Want to learn more about Silence Therapeutics plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Silence Therapeutics plc.

Silence Therapeutics plc’s Stock Price as of Market Close

As of April 22, 2026, 11:33 AM, CST, Silence Therapeutics plc’s stock price was $7.800.

Silence Therapeutics plc is up 0.91% from its previous closing price of $7.730.

During the last market session, Silence Therapeutics plc’s stock traded between $7.700 and $7.970. Currently, there are approximately 47.23 million shares outstanding for Silence Therapeutics plc.

Silence Therapeutics plc’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Silence Therapeutics plc Stock Price History

Silence Therapeutics plc’s (SLN) price is currently up 48.01% so far this month.

During the month of April, Silence Therapeutics plc’s stock price has reached a high of $8.140 and a low of $5.180.

Over the last year, Silence Therapeutics plc has hit prices as high as $8.140 and as low as $2.960. Year to date, Silence Therapeutics plc’s stock is up 28.29%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Silence Therapeutics plc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of April 21, 2026,, no analysts have changed their rating of Silence Therapeutics plc’s stock over the last month.

Additionally, you'll want to evaluate Silence Therapeutics plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Silence Therapeutics plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Silence Therapeutics plc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Silence Therapeutics plc (SLN) by visiting AAII Stock Evaluator.

Relative Price Strength of Silence Therapeutics plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 21, 2026, Silence Therapeutics plc has a weighted four-quarter relative price strength of 21.94%, which translates to a Momentum Score of 91 and is considered to be Very Strong.

Want to learn more about how Silence Therapeutics plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Silence Therapeutics plc Stock Price: Bottom Line

As of April 22, 2026, Silence Therapeutics plc’s stock price is $7.800, which is up 0.91% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Silence Therapeutics plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.